[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.159.197.114. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Observation
May 2004

Unexplained Hypereosinophilia and the Need for Cytogenetic and Molecular Genetic Analyses

Author Affiliations

From the Department of Dermatopathology, Quest Diagnostics, Tucker, Ga (Drs Smith and Skelton); Dermatology, St Vincent Hospital, Birmingham, Ala (Dr Jacobson); and the Department of Pathology, University of Alabama at Birmingham (Dr Hamza). The authors have no relevant financial interest in this article. Dr Hamza is now with the Department of Pathology, University of Manitoba, Winnipeg.

Arch Dermatol. 2004;140(5):584-588. doi:10.1001/archderm.140.5.584
Abstract

Background  Idiopathic hypereosinophilic syndrome (HES) is a diagnosis made after the exclusion of other causes of eosinophilia. However, differentiation of idiopathic HES from eosinophilic leukemia is sometimes difficult. In some cases, these diagnoses can be differentiated by cytogenetic or molecular findings, as illustrated in the patients described herein.

Observations  We describe 3 patients with HES and associated pruritus; 1 patient also had recurrent lesions of eosinophilic cellulitis. All 3 patients were initially diagnosed as having idiopathic HES, but after evaluation and demonstration of molecular abnormalities, they were classified as having eosinophilic leukemia.

Conclusions  Patients with a diagnosis of idiopathic HES should be evaluated for cytogenetic or molecular genetic abnormalities. These abnormalities can establish a diagnosis of chronic eosinophilic leukemia and may provide clues for emerging therapies.

Idiopathic hypereosinophilic syndrome (HES) is characterized by unexplained hypereosinophilia (eosinophil counts >1500/µL persisting for ≥6 months) that may lead to organ damage.1 At times, idiopathic HES may be difficult to differentiate from chronic eosinophilic leukemia (EL). Features that have been said to favor EL include hepatomegaly, splenomegaly, anemia, and thrombocytopenia. However, the diagnosis of EL can be made if blast crisis or a soft tissue tumor of myeloblasts (granulocytic sarcoma) develops, if a clonal eosinophilic proliferation is found, or if characteristic molecular or cytogenetic abnormalities are present.1,2

All 3 patients were initially diagnosed as having idiopathic HES. Further hematologic workup showed a chromosomal translocation in 1 patient. A characteristic chromosomal deletion seen in many patients with HES was found in the other 2 patients. Both abnormalities can result in constitutive activation of tyrosine kinase pathways and are consistent with the uncontrolled growth seen in chronic EL. The constitutive activation of tyrosine kinase pathways suggests that inhibitors of these pathways could have a role in therapy. The underlying molecular and chromosomal abnormalities may also have implications for the initial response and for the duration of response.

REPORT OF CASES

All 3 patients had at least 2 documented absolute peripheral blood eosinophil counts greater than 1500/µL for greater than 6 months (Table 1). Initially, all 3 patients had negative results of evaluations for a known cause of eosinophilia, including an evaluation for parasitic infections, and clinical or laboratory findings consistent with eosinophilic disorders, including Churg-Strauss vasculitis, chronic eosinophilic pneumonia, eosinophilic gastroenteritis, and episodic angioedema and eosinophilia. All 3 patients had histologic evidence of tissue infiltration by eosinophils or objective evidence of tissue damage in an organ system associated with eosinophilia. One patient had pruritus with recurrent erythematous nodules and plaques that showed features consistent with eosinophilic cellulitis (Table 1 and Figure 1). This patient also had gastrointestinal complaints and splenomegaly on physical examination, which were confirmed by computed tomography. The 2 other patients had pruritus with transient erythematous eruptions. Both these patients had obstructive pulmonary disease on pulmonary function testing, with interstitial infiltrates on chest computed tomographic scans; in addition, 1 patient had an episode of deep vein thrombosis and the other had progressive peripheral neuropathy (Table 1).

Patients With Hypereosinophilic Syndrome With Cytogenetic Changes Consistent With Chronic Eosinophilic Leukemia Responding to Imatinib Therapy
Patients With Hypereosinophilic Syndrome With Cytogenetic Changes Consistent With Chronic Eosinophilic Leukemia Responding to Imatinib Therapy
Low-power (A) and high-power (B) views of biopsy sections from the first patient showing a dense eosinophilic infiltrate with flame figures (hematoxylin-eosin, original magnification ×30 and ×300, respectively).

Low-power (A) and high-power (B) views of biopsy sections from the first patient showing a dense eosinophilic infiltrate with flame figures (hematoxylin-eosin, original magnification ×30 and ×300, respectively).

The first patient had been diagnosed more than 3 years earlier and was initially treated with prednisone, but periodic flairs became persistent. After approximately 1 year, the patient underwent cytogenetic studies that showed chromosomal translocation t(5;12)(q33;p13). The patient was then given a presumptive diagnosis of chronic EL and was treated with hydroxyurea for approximately 14 months. Although the patient initially did well, his response was short-lived, and he again developed symptoms, including recurrent lesions of eosinophilic cellulitis and hypereosinophilia; he was administered interferon alfa without response. The patient was then given imatinib mesylate (Gleevec; Novartis Pharmaceuticals Corp, East Hanover, NJ), 600 mg/d, with initial rapid resolution of symptoms and eosinophilia. After 4 months of imatinib therapy, the patient experienced blast crisis and was administered flavopiridol and depsipeptide.

In patients 2 and 3, cytogenetic analysis of unstimulated bone marrow cells showed no evidence of a clonal hematopoietic process. In addition, in both patients, results of polymerase chain reaction (PCR)–based T-cell gamma receptor and immunoglobulin heavy chain gene rearrangement analysis of peripheral blood mononuclear cells or bone marrow aspirates and flow cytometric analysis of T-cell surface markers were negative for clonality and an aberrant surface profile. RNA was then isolated from peripheral blood mononuclear cells of both patients using TRIzol Reagents (Invitrogen Corp, Carlsbad, Calif) and analyzed by nested PCR using primers FIP1L1-F1 (5′-acctggtgctgatcttctgat) and platelet-derived growth factor receptor (PDGFR) α-R1 (5′-tgagagctgtttttcactgga) during the first PCR and primers FIP1L1-F2 (5′-aaagaggatacgaatgggacttg) and PDGFRα-R2 (5′-gggaccggcttaatccatag) for the second PCR. Control reverse transcriptase PCR for GAPDH was performed using the primers GAPDH (glyceraldehyde-3-phosphate dehydrogenase)-F (5′-tggaaatcccatcaccatct) and GAPDH-R (5′-gtcttctgggtggcagtgat). Products of PCR were cloned in the pGEM-T Easy Vector System (Promega Corp, Madison, Wis), and cloned products were sequenced on an ABI system (PerkinElmer Inc, Boston, Mass). Both patients showed fusion of the FIP1L1 gene to the PDGFRα.

Patients 2 and 3 were subsequently given imatinib mesylate, 400 mg daily, and they both had rapid clearing of symptoms with normalization of eosinophil counts; they have remained clear for more than 8 months, with no apparent adverse effects from the medication.

COMMENT

Hypereosinophilic syndrome is a rare hematologic disorder characterized by sustained overproduction of eosinophils in the bone marrow, eosinophilia, tissue infiltration, and organ damage. Hypereosinophilia (>1500/µL for >6 months) occurs in the absence of other causes of eosinophilia, including parasitic infections, immune dysregulation, and allergies. Other symptoms of organ involvement affect the heart, lungs, gastrointestinal system, central and peripheral nervous systems, and skin. Total leukocyte counts are usually less than 25 000/µL, with 30% to 70% eosinophilia, and bone marrow eosinophils are increased 30% to 60%; rarely, there are myeloblasts.3 Although it can be difficult to assess the clonality of HES, rare cases show karyotypic abnormalities.4,5

In female patients, clonality by investigation of X-linked polymorphisms of the phosphoglycerate kinase genes and the human androgen receptor gene (Humara) can be performed.6,7 A skewed distribution of expression of X chromosome genes provides presumptive evidence of clonality and neoplasia; however, 90% of patients with idiopathic HES are males, and, thus, X-linked polymorphisms are not applicable in most patients.1 In rare cases of HES, a clone of T cells or, more rarely, a polyclonal T proliferation secretes cytokines that induce hypereosinophia.811 The interleukin 5 concentration is usually elevated, but increased levels of interleukin 4 and granulocyte-macrophage colony-stimulating factor have also been reported.811 Clonal and polyclonal T-cell proliferations show an abnormal phenotype CD3CD4+ or CD3+CD4CD8, and both seem to depend on exogenous signals for proliferation and cytokine production.12

Eosinophilic proliferation is common in a variety of defined subtypes of chronic myeloid leukemia, including chronic EL or chronic myelomonocytic leukemia with eosinophilia associated with translocation t(5;12)(q33;p13) and chronic EL with evolution to acute myeloid leukemia and T-lineage lymphoblastic lymphoma associated with t(8;13)(p11;q12) or other cytogenetic aberrations with an 8p1-12 breakpoint.1,1317 The initial oncogenic event in the development of EL and other chronic myeloid leukemias mainly involves genes for membrane receptors or their signaling pathways, including PDGFRα and PDGFRβ and fibroblast growth factor receptor 1, as well as Janus kinase 2.1 Activation of these pathways results in constitutive activation of tyrosine kinases.1 In contrast, in most de novo acute myeloid leukemias, transcription factor genes are affected.1

The first patient had a previously identified translocation in the myeloid cells, t(5;12)(q33;p13). The likely mechanism of leukemogenesis with this translocation is the fusion of the tel gene and the PDGFRβ, resulting in constitutive activation of the tyrosine kinase domain of PDGFRβ.17 Leukemogenesis is probably mediated through c-Myc because a threshold concentration of active Myc protein is necessary to permit transformation of cells by the fusion gene.18 Rarely, different translocations involving the tel gene, t(9;15)(p24;q15;p13) with Janus kinase 2 and t(5;12)(q31;p13), have also been described. The latter translocation may correspond to activating mutations for the production of interleukin 5 at the 5q31 locus.1 Other cytogenetic abnormalities found in association with chronic EL include fusion of zinc finger 198–fibroblast growth factor receptor 1, trisomy 15, t(8;9)(p22;p23), t(3;9;5)(q25;q34;q33), and t(8;9)(p11;q32-34) and t(6;8)(q27;p12).1,18,19 The latter 2 translocations have a poor prognosis, with a high incidence of acute transformation, and the best therapeutic option for young patients with these translocations is probably stem cell transplantation early after diagnosis.1 There is overlap between eosinophilic myelodysplastic syndrome and chronic EL. However, eosinophilia is uncommon in myelodysplastic syndrome, and the greatest prevalence is in cases of therapy-related myelodysplastic syndrome showing a t(1;7).19 Patients 2 and 3 had a molecular defect similar to that found in greater than 50% of patients originally diagnosed as having idiopathic HES.20 They showed that fusion of the FIP1L1 gene to the PDGFRα with a deletion on 4q12 results in constitutive activation of PDGFRα tyrosine kinase.

Treatment of HES has had as its goal limitation of organ damage by controlling eosinophilia. In idiopathic HES, prednisone, interferon alfa, psoralen–UV-A, hydroxyurea, cyclosporine, and, less commonly, other cytotoxic therapies have been used.21,22 The clinical manifestations and responses to therapy are variable in patients with HES, which may reflect the underlying variable etiology of the disorder. Now that it is realized that some of these patients do in fact have clonal proliferations of myeloid cells that represent chronic EL and not reactive myeloid proliferations, the failure of therapy and the progression in some patients are better understood.

There are no agreed-on guidelines for the treatment of chronic EL.2123 Although complete remissions have occurred with interferon alfa therapy, these remissions are often short-lived.23 Imatinib, a 2-phenylaminopyrimidine-based tyrosine kinase inhibitor that is approved for the treatment of BCR-ABL–positive chronic myeloid leukemia and acute lymphoblastic leukemia, has recently been used successfully in patients with HES.20,2426 In addition to the ABL tyrosine kinase, imatinib also inhibits the type III transmembrane receptor KIT and PDGRRs.20,2426 Clinical response to imatinib therapy in patients diagnosed as having idiopathic HES led to the discovery that more than 50% of these patients had fusion of the PDGFRα and FIP1L1 genes generated by an interstitial deletion on 4q12. This fusion product results in constitutively activated PDGFR tyrosine kinase activity, which is potentially inhibited by imatinib.20 Several investigative groups2729 have now confirmed that some cases of HES do respond to imatinib treatment.

Chronic myeloid leukemia, the first disease indication for imatinib therapy, is a myeloproliferative disease that overlaps with EL. Chronic myeloid leukemia is a triphasic disease beginning with a relatively innocuous chronic phase, in which 50% of patients can be asymptomatic for an average of 4 to 5 years, with progression to an accelerated phase lasting 6 to 18 months, and terminating in fatal blast crisis with a duration of approximately 6 months. With progression to blast crisis, the malignant clones acquire additional genetic mutations, including trisomy 8, isochromosome I (17q), and trisomy 19.30 Thus, the therapeutic window for cure is early in disease.

Imatinib binds to tyrosine kinases BCR-ABL, KIT, PDGFRα, and PDGFRβ, blocking the binding of adenosine triphosphate.31 This prevents the phosphorylation of substrate on the kinases. Imatinib has a low toxicity profile compared with many other cytotoxic agents. The most common adverse effects are diarrhea, reflux, taste disturbances, peripheral edema, nausea, and skin eruptions in up to 30% of patients.31 The skin eruptions are mainly maculopapular exanthemas; however, Stevens-Johnson syndrome and acute pustular exanthema have been reported.3234 There are also reports of depigmentation, including graying of hair with imatinib therapy.35 The depigmentation is speculated to be secondary to the inhibition of KIT, which is expressed on skin basal cells, melanocytes, and mast cells.35 However, there are also reports of hyperpigmentation and darkening of hair color in some patients.36 In patients taking high doses, 800 to 1000 mg/d, thrombocytopenia and neutropenia have occurred.31

Imatinib is metabolized in the liver primarily by cytochrome (CYP)3A4/5. Thus, inducer and inhibitors of this enzyme should be used with caution.31,34 Imatinib is a weak inhibitor of CYP2D6 and CYP2C9, and drugs metabolized by these enzymes should be monitored, particularly warfarin, which has been associated with central nervous system hemorrhage with imabinib.31,34

Resistance to imatinib can occur through gene amplifications resulting in higher protein levels and gene mutations in the ATP-binding pocket resulting in the inability of imatinib to competitively bind out ATP. In addition, increased expression of the multidrug resistance (MDR) 1 gene correlates with resistance to imatinib.31MDR-1 encodes P-glycoprotein, a member of the ATP-binding cassette protein family that functions to remove toxic molecules from cells.31 Inherited polymorphisms in the MDR-1 gene may explain some of the variable sensitivity to imatinib in different patients.37,38

The first patient in this study developed resistance to imatinib within 4 months. Perhaps his primary cytogenetic changes or his previous therapies, including hydroxyurea and interferon alfa, predisposed him to more rapid development of resistance with the development of blast crisis.1

Genetic and biochemical data support that Ras activation has a central role in the oncogenic mechanisms of the tyrosine kinases that are inhibited by imatinib. The combination of H-ras inhibitors, that is, farnesyl transferase inhibitors with imatinib mesylate, seems to increase the initial response and the duration of response to imatinib.37 Combinations of imatinib with interferon alfa, vincristine sulfate, daunorubicin hydrochloride, or cytarabine arabinoside, or more novel compounds such as the Janus kinase 2 inhibitor AG490, are also being evaluated, and some of these combinations seem to show some synergy.38 Treatment with histone deacetylase inhibitors such as depsipeptide and cell cycle modulators such as flavopiridol, as were used in the first patient who entered blast crisis, are also being evaluated in combination with imatinib to increase the its efficacy and delay the development of resistance.39

In conclusion, cytogenetic and molecular genetic analyses are probably indicated in all patients who meet the criteria for idiopathic HES, especially since they may define defects that result in activation of molecular pathways for which we now have inhibitors.2

Back to top
Article Information

Corresponding author: Henry Skelton, MD, Department of Dermatopathology, Quest Diagnostics, 1777 Montreal Circle, Tucker, GA 30084 (e-mail: henry.g.skelton@questdiagnostics.com).

Accepted for publication August 7, 2003.

References
1.
Bain  BJ Hypereosinophilia cytogenic and/or molecular Curr Opin Hematol. 2000;721- 25
PubMedArticle
2.
Yamada  TShiohara  KKatsuki  K A case of idiopathic hypereosinophilic syndrome complicated with disseminated intravascular coagulation Am J Hematol. 1998;58100- 101
PubMedArticle
3.
Weller  PFBubley  GJ The idiopathic hypereosinophilic syndrome Blood. 1994;832759- 2779
PubMed
4.
Luppi  MMarasca  RMorselli  MBarozzi  PTorelli  G Clonal nature of hypereosinophilic syndrome Blood. 1994;84349- 350
PubMed
5.
Chang  HWLeong  KHKoh  DRLee  SH Clonality of isolated eosinophils in the hypereosinaophilic syndrome Blood. 1999;931651- 1658
PubMed
6.
Luppi  Mmarasca  RMorselli  MBaozzi  PTorelli  G Clonal nature of the hypereosinophilic syndrome Blood. 1994;84349- 350
PubMed
7.
Chang  H-WLeong  K-HKoh  D-RLee  S-H Clonality of isolated eosinophilia in the hypereosinophilic syndrome Blood. 1999;931651- 1657
PubMed
8.
Raghavacher  AFleischer  SFrickhofen  NHeimpel  HFleischner  S T lymphocyte control of human eosinophilic granulopoiesis: clonal analysis of an idiopathic hypereosinophilic syndrome J Immunol. 1987;1393753- 3758
PubMed
9.
Cogan  ESchandene  LCogan  E  et al.  Clonal proliferation of type 2 helper T cells in a man with hypereosinophilic syndrome N Engl J Med. 1994;330535- 538
PubMedArticle
10.
Kitano  KIchkawa  NMahbub  BUeno  MIto  TShimodaira  D Eosinphilia associated with proliferation of CD3+r+8-alfa/beta T cells with chromosome 16 abnormalities Br J Haematol. 1996;92315- 317
PubMedArticle
11.
Bank  IReshef  ABenjaminov  MRosenthal  ERechavi  GMonselse  Y Role of gamma/delta T cells in a patient with CD4+/CD3lymphocytosis, hypereosinophilia and high levels of IgE J Allergy Clin Immunol. 1998;102621- 630
PubMedArticle
12.
Roufosse  FSchandene  LSibile  C  et al.  T-cell receptor–independent activation of clonal Th2 cells associated with chronic hypereosinophilia Blood. 1999;94994- 1002
PubMed
13.
Bain  BJ Interactive Haematology Imagebank (book on CD-ROM)  Oxford, England Blackwell Science1999;
14.
Golub  TRBarker  GFLovett  MGilliland  DG Fusion of PDGF receptor β to a novel ets-like gene, tel, in chronic myelomonocytic leukemia with t(5;12) chromosomal translocation Cell. 1994;77307- 316
PubMedArticle
15.
Tomasson  MHWilliams  IRHassejian  RUdomsakhdi  CMcGrath  SMSchwaller  J Tel/PDGRbetaR induces haematologic malignancies in mice that respond to a specific tyrosine kinase inhibitor Blood. 1999;931707- 1714
PubMed
16.
Aprikian  AGMontgomery  BBowen-Pope  DFHickstein  DD Mechanism of Tel/PDGFRbeta mediated myeloproliferation in transgenic mice [abstract] Blood. 1997;90(suppl 1)412a
17.
Peeters  PRaynaud  SDCools  JWlodarska  LGrosgeorge  JPhilip  P Fusion of TEL, the ETS variant gene 6 (ETV6), to the receptor-associated kinase JAK2 as a result of t(9;12) in a lymphoid and t(9;15;12) in a myeloid leukemia Blood. 1997;902535- 2540
PubMed
18.
Bourgeade  M-FDefachelles  ASCayre  YE Myc is essential for transformation by TEL/platelet-derived growth factor receptor beta Blood. 1998;913333- 3339
PubMed
19.
Forrest  DLHorsman  DEJensen  CL  et al.  Myelodysplastic syndrome with hypereosinophilia and a nonrandom chromosomal abnormality dic(1;7): confirmation of eosinophil clonal involvement by fluorescence in situ hybridization Cancer Genet Cytogenet. 1998;10765- 68
PubMedArticle
20.
Xiao  SNalolu  SRAster  JC  et al.  FGFR1 is fused with a novel zinc-finger gene, ZNF198, in the t(8;13) leukaemia/lymphoid syndrome Nat Genet. 1998;1884- 87
PubMedArticle
21.
Yanada  OKitahara  KImamura  KOzasa  HOkada  MMizoguchi  H Clinical and cytogenetic remission induced by interferon-alfa in a patient with chronic eosinophilic leukemia associated with a unique t(3;9;5) translocation Am J Hematol. 1998;58137- 141
PubMedArticle
22.
Parrillo  JEFauci  ASWolff  SM Therapy of the hypereosinophilic syndrome Ann Intern Med. 1978;89167- 172
PubMedArticle
23.
Malbrain  MLVan den Bergh  HZachee  P Further evidence for the clonal nature of the idiopathic hypereosinophilic syndrome: complete haematological and cytogenetic remission induced by interferon-alpha in a case with a unique chromosomal abnormality Br J Haematol. 1996;92176- 183
PubMedArticle
24.
Druker  BJSawyers  CLKantarijian  H  et al.  Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome N Engl J Med. 2001;3441038- 1042[published correction appears in N Engl J Med. 2001;345:232]
PubMedArticle
25.
Druker  BJTalpaz  MResta  DJ  et al.  Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia N Engl J Med. 2001;3441031- 1037
PubMedArticle
26.
Cools  JDeAngelo  DJGotlib  J  et al.  A tyrosine kinase created by fusion of the PDGFRA and FIPL1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome N Engl J Med. 2003;3481201- 1214
PubMedArticle
27.
Schwartz  RS The hypereosinophilic syndrome and the biology of cancer N Engl J Med. 2003;3481199- 1200
PubMedArticle
28.
Klion  ADNoel  PAkin  C  et al.  Elevated serum tryptase levels identify a subset of patients with a myeloproliferative variant of idiopathic hypereosinophilic syndrome associated with tissue fibrosis, poor prognosis, and imatinib responsiveness Blood. 2003;1014660- 4666
PubMedArticle
29.
Schaller  JLBurkland  GA Case report: rapid and complete control of idiopathic hypereosinophilia with imatinib mesylate MedGenMed. 2001;39
PubMed
30.
Paterson  SCSmith  KDHolyoake  TLJorgensen  HG Is there a cloud in the silver lining for imatinib? Br J Cancer. 2003;88983- 987
PubMedArticle
31.
Deininger  MWNO'Brien  SGFord  JMDruker  BJ Practical management of patients with chronic myeloid leukemia receiving imatinib J Clin Oncol. 2003;211637- 1647
PubMedArticle
32.
Hsiao  LTChung  HMLin  JT  et al.  Stevens-Johnson syndrome after treatment with STI571: a case report Br J Haematol. 2002;117620- 622
PubMedArticle
33.
Sasaki  KYamamoto  TKishi  MYokozeki  HNishioka  K Acute exanthematous pustular drug eruption induced by mexiletine Eur J Dermatol. 2001;11469- 471
PubMed
34.
O'Brien  SGPeng  BDutreix  C  et al.  A pharmacokinetic interaction of Glivec and simvastatin, a cytochrome 3A4 substrate in patients with chronic myeloid leukemia [abstract] Blood. 2001;98(suppl)141a
35.
Etienne  GCony-Makhoul  PMahon  FX Imatinib mesylate and gray hair N Engl J Med. 2002;347446- 447
PubMedArticle
36.
Lammie  ADrobnjak  MGerald  W  et al.  Expression of c-Kit and Kit ligand proteins in normal human tissues J Histochem Cytochem. 1994;421417- 1425
PubMedArticle
37.
Nakajima  ATauchi  TSumi  MBishop  WROhyashiki  K Efficacy of SCH66336, a farneyl transferase inhibitor, in conjunction with imatinib against BCR-ABL–positive cells Mol Cancer Ther. 2003;2219- 224
PubMedArticle
38.
Druker  BJ Overcoming resistance to imatinib by combining targeted agents Mol Cancer Ther. 2003;2225- 226
PubMed
39.
Rosato  RRGrant  S Histone deacetylase inhibitors in cancer therapy Cancer Biol Ther. 2003;230- 37
PubMed
×